Axsome Therapeutics Inc., a US-based biopharmaceutical firm, is dedicated to the creation of innovative treatments for central nervous system (CNS) disorders. The company has a strong commercial product portfolio that includes Auvelity (dextromethorphan-bupropion), an N-methyl-D-aspartate receptor antagonist, and Sunosi (solriamfetol), aimed at the treatment of major depressive disorder and excessive daytime sleepiness, respectively. Axsome Therapeutics is also actively developing AXS-05, currently in Phase III clinical trials to treat Alzheimer's disease agitation, and a medication which has completed Phase II clinical trials for smoking cessation, among other conditions. Other investigational medicines include AXS-07 for the acute treatment of migraine, AXS-12 for narcolepsy treatment, AXS-14 for fibromyalgia treatment, and Solriamfetol as a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed Phase 2 trials for treating attention-deficit/hyperactivity disorder. The company has a research collaboration agreement with Duke University to evaluate AXS-05 for smoking cessation. Incorporated in 2012 and located in New York, Axsome Therapeutics Inc. is actively advancing the fight against CNS disorders with cutting-edge treatments.